GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
LENS - Long-term Eltrombopag Observational Study
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 164
- Registration Number
- NCT00643929
- Locations
- 🇬🇧
GSK Investigational Site, Morriston, United Kingdom
A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 306
- Registration Number
- NCT00642148
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 38
- Registration Number
- NCT00640328
A Study in Elderly Subjects With Pneumonia to Support the Development of Bacteriological Diagnostic Assays
- Conditions
- Infections, Streptococcal
- Interventions
- Procedure: Blood sampleProcedure: Urine sample
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT00637351
- Locations
- 🇧🇪
GSK Investigational Site, Yvoir, Belgium
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
- Conditions
- Infections, PapillomavirusPapillomavirus Vaccines
- Interventions
- Biological: Engerix™Biological: Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 152
- Registration Number
- NCT00637195
- Locations
- 🇧🇪
GSK Investigational Site, La Louvière, Belgium
Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine
- Conditions
- DiphtheriaPoliomyelitisAcellular PertussisTetanus
- Interventions
- Biological: Boostrix-Polio
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 415
- Registration Number
- NCT00635128
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
- Conditions
- Parkinson DiseaseParkinson's Disease
- Interventions
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 419
- Registration Number
- NCT00632736
- Locations
- 🇬🇧
GSK Investigational Site, Swansea, United Kingdom
A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 99
- Registration Number
- NCT00633022
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations
- Conditions
- Influenza
- Interventions
- Biological: Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)Biological: Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 720
- Registration Number
- NCT00633074
- Locations
- 🇪🇪
GSK Investigational Site, Tartu, Estonia
Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 247
- Registration Number
- NCT00633217
- Locations
- 🇺🇸
GSK Investigational Site, Morgantown, West Virginia, United States